THE 30-SECOND OVERVIEW
At a glance
Ipamorelin and CJC-1295 are constantly mentioned in the same sentence, which makes it easy to assume they are variations on one theme. They are not. They act on two different receptors, belong to two different structural families, and were developed by different routes. The reason they appear together is that their separate mechanisms converge on the same endpoint, which is release of growth hormone from the pituitary.
Two receptors, two families
CJC-1295 is a growth hormone-releasing hormone analogue. Its backbone is GHRH(1-29), the active fragment of the native hypothalamic hormone, stabilised with four amino acid substitutions and, in the DAC version, tethered to serum albumin for a multi-day circulating life. It binds the GHRH receptor on pituitary somatotrophs, the same receptor the body's own releasing hormone uses. We cover the two versions of this molecule in detail in CJC-1295 DAC vs no DAC.
Ipamorelin comes from the other side of the regulatory system. It is a pentapeptide, just five residues (Aib-His-D-2-Nal-D-Phe-Lys), and it binds the growth hormone secretagogue receptor GHS-R1a. That is the receptor the stomach hormone ghrelin acts on, and the one shared with MK-677 liquid, an orally active small molecule rather than a peptide, which is why MK-677 turns up in the same secretagogue literature. Ipamorelin shares no sequence with ghrelin or with GHRH; it emerged from Novo Nordisk's medicinal chemistry programme on growth hormone-releasing peptides in the 1990s.
So the honest comparison is not between two similar peptides. It is between two different levers on the same axis.
Why ipamorelin's selectivity mattered
The ghrelin-receptor peptides that preceded ipamorelin, GHRP-6 and GHRP-2, had a known problem: alongside growth hormone they provoked release of ACTH, cortisol, and prolactin. For research purposes that is noise, and for the drug-development programmes of the time it was a liability.
Raun and colleagues characterised ipamorelin in 1998 and reported the finding that made the compound's name: it stimulated growth hormone release with potency comparable to GHRP-6, but even at doses more than a hundredfold above threshold it produced no meaningful rise in ACTH or cortisol. They described it as the first selective growth hormone secretagogue. That selectivity is the specific property that keeps ipamorelin in research use while its predecessors have largely faded.
Different signal shapes
The two compounds also differ in the shape of the stimulus they deliver.
Ipamorelin is short-acting. Its half-life in circulation is on the order of a couple of hours at most, and the growth hormone response it provokes is a discrete pulse. CJC-1295 with DAC sits at the opposite extreme: Teichman's 2006 human study measured elevated growth hormone and IGF-1 for up to two weeks after a single injection. One compound asks the pituitary a question; the other leans on it.
There is also a mechanistic wrinkle worth knowing. GHRH-receptor signalling and ghrelin-receptor signalling are not redundant. GHRH stimulates synthesis and release; ghrelin-receptor agonists amplify the release and also suppress somatostatin, the hormone that otherwise brakes the system. In animal and human work the two signals together produce a larger response than either alone, which is the entire rationale for studying them in combination and why a combined preparation such as the CJC-1295 + Ipamorelin blend exists as a single vial.
What the published record covers, and what it does not
Ipamorelin's published record is real but narrow: the original pharmacology, animal studies on bone and gastrointestinal motility, and early-phase human work including a clinical programme in postoperative ileus that was discontinued for lack of efficacy on its endpoint. It has no approved indication anywhere.
CJC-1295's human data comes principally from the Teichman and Ionescu studies of the mid-2000s, which established pharmacokinetics and hormone responses in healthy adults. Its development programme was halted and it likewise holds no approval.
Neither compound, in other words, carries anything like a phase 3 record, and claims about long-term effects of either are extrapolation rather than evidence. The comparison with the better-documented GHRH analogues is instructive: tesamorelin, which we compare against its relatives in Tesamorelin vs CJC-1295, reached approval on an 800-participant phase 3 programme. Nothing in the ipamorelin or CJC-1295 literature approaches that.
The takeaway
Ipamorelin is a small, selective ghrelin-receptor agonist that delivers a clean, short pulse. CJC-1295 is a stabilised GHRH analogue whose DAC version delivers sustained receptor pressure over days. They are not competitors so much as complements, and the research that pairs them does so deliberately, one compound per receptor. For format-specific work, both are available as single compounds, ipamorelin as a vial or nasal spray, alongside the combined preparation.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
2. Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805.
3. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 91(12), 4792-4797.
